Publications

2025

‍–

Science Direct

The safety and efficacy of extended use of an oral shape-shifting superabsorbent hydrogel capsule for weight loss: The ELECT extension study

View Publication

2025

‍–

International Journal of Obesity

Quality of life improvements associated with weight loss using a novel shape-shifting hydrogel capsule: RESET study results

View Publication

2025

‍–

Clinical Obesity

Association of the Early Response to an Oral Shape- Shifting Superabsorbent Hydrogel Capsule With Weight Loss

View Publication

2025

‍–

Obesity Pillars

Weight and cardiometabolic effects of a novel oral shape-shifting superabsorbent hydrogel capsule: Prespecified and exploratory analysis of the Epitomee capsule RESET study

View Publication

2024

‍–

Obesity Journal

Efficacy and safety of a novel oral hydrogel capsule in adults with overweight or obesity: the pivotal randomized RESET study

View Publication

2023

‍–

Obesity Pillars

Effects of an oral biodegradable device used for 12 weeks on weight reduction, cardiovascular risk factors, satiety, snacking, and meal size

View Publication

2019

‍–

Obesity Science & Practice

Safety, tolerability and efficacy of a novel self-use biodegradable device for management of obesity

View Publication

The Epitomee^® capsule is intended to facilitate weight loss in patients aged 18 and older who are overweight (BMI 25-30 kg/m²) or obese (BMI 30-40 kg/m²) who have not achieved desired results through diet and exercise. The Epitomee^® capsule is intended to be used as an adjunct to diet and exercise.

You cannot take Epitomee^® if you are pregnant or have had allergic reaction to one or more of the Epitomee^® components. Most side effects were mild and similar to placebo. Epitomee is a prescription device and should be taken under the supervision of a healthcare provider.